Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dabigatran Etexilate Tablet vs Capsule
NCT03070171Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dabigatran in thromboembolism (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (tz) for Free Dabigatran at 48 hours and Maximum measured concentration of the analyte in plasma for Free Dabigatran at 48 hours. Started Mar 2017; status: completed.
02
Drugs
dabigatran
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT03070171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03070171.